6FTP image
Entry Detail
PDB ID:
6FTP
Title:
Crystal form 1 of Alpha1-antichymotrypsin variant DBS-II-allo: an allosterically modulated drug-binding serpin for doxorubicin
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2018-02-22
Release Date:
2018-05-23
Method Details:
Experimental Method:
Resolution:
1.80 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 31 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Alpha-1-antichymotrypsin
Mutations:L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F D278E A349R V355L K356E I357V T358L L359F L360Q
Chain IDs:A
Chain Length:369
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Alpha-1-antichymotrypsin
Mutations:S361G A362P P382D T383N D384F Q386W N387S
Chain IDs:B
Chain Length:40
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Design of an allosterically modulated doxycycline and doxorubicin drug-binding protein.
Proc. Natl. Acad. Sci. U.S.A. 115 5744 5749 (2018)
PMID: 29760101 DOI: 10.1073/pnas.1716666115

Abstact

The allosteric interplay between distant functional sites present in a single protein provides for one of the most important regulatory mechanisms in biological systems. While the design of ligand-binding sites into proteins remains challenging, this holds even truer for the coupling of a newly engineered binding site to an allosteric mechanism that regulates the ligand affinity. Here it is shown how computational design algorithms enabled the introduction of doxycycline- and doxorubicin-binding sites into the serine proteinase inhibitor (serpin) family member α1-antichymotrypsin. Further engineering allowed exploitation of the proteinase-triggered serpin-typical S-to-R transition to modulate the ligand affinities. These design variants follow strategies observed in naturally occurring plasma globulins that allow for the targeted delivery of hormones in the blood. By analogy, we propose that the variants described in the present study could be further developed to allow for the delivery of the antibiotic doxycycline and the anticancer compound doxorubicin to tissues/locations that express specific proteinases, such as bacterial infection sites or tumor cells secreting matrix metalloproteinases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures